AI-fo­cused No­table Labs score $40M in fund­ing; Seat­tle Ge­net­ics/Astel­las sub­mit mar­ket­ing ap­pli­ca­tion for en­for­tum­ab ve­dotin

→ The AI ex­perts at No­table Labs have gar­nered an­oth­er $40 mil­lion to scale their au­to­mat­ed lab­o­ra­to­ry and an­a­lyt­ics plat­form. De­signed to match pa­tients to clin­i­cal tri­als by pre­dict­ing quick­ly who are most like­ly to re­spond to a can­cer drug, the start­up has pitched it­self as an ad­vo­cate for pa­tients and fa­cil­i­ta­tor to phar­ma com­pa­nies. With the Se­ries B cash, No­table Labs plans to ex­pand their plat­form both in terms of ge­og­ra­phy — build­ing labs out­side of North Amer­i­ca — and can­cer types (it’s cur­rent­ly fo­cused on hema­to­log­i­cal can­cers).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.